US EditionLive from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin ...
4 Articles
4 Articles
Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin ...
ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest clinical data from its…
Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors - Ascentage Pharma Group (NASDAQ:AAPG)
ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ:AAPG, HKEX: 6855)), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest clinical data from its Phase II study of the MDM2-p53 inhibitor alrizomadlin (APG-115) as a single agent or in combination with PD-1 inhibitor toripalimab in patients with advanced adenoid cystic carcino…
ROCKVILLE, Md. and SUZHOU, China, June 3, 2025 /PRNewswire/ — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a leading biopharmaceutical company committed to developing innovative medicines in oncology and other fields, announced that the company has presented the latest progress of its Phase II clinical study of the MDM2-p53 inhibitor alrizomadlin (APG-115) alone or in combination with the PD-1 inhibitor toripalimab in patients with advanced aden…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
